Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Non-Insulin Therapies For Diabetes Market Growth Performance Trended Historically, And What Lies Ahead?

Over the past few years, there’s been robust growth in the market size of non-insulin therapies for diabetes. It’s projected to increase from $19.98 billion in 2024 to $21.41 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.1%. The escalation during the historic period is largely due to rising cases of diabetes, heightened awareness of diabetes management techniques, increased healthcare spending, lifestyle alterations resulting in higher incidence rates, a spike in diagnoses, more government initiatives towards diabetes care, and the surge in investment for pharmaceutical research and development.

What Is the Forecast for the Non-Insulin Therapies For Diabetes Market Size Through 2029?

It is forecasted that the market size for non-insulin diabetes treatments will experience considerable expansion in the next few years, reaching $27.9 billion in 2029 with a CAGR of 6.8%. The projected growth during this period can be associated with several factors such as an increase in diabetes occurrence, heightened awareness regarding diabetes control, a rise in the use of combination therapies, a larger aging population, escalating healthcare expenses, the proliferation of telemedicine, and a growing favorability towards oral meds. Key trends anticipated during this forecast period encompass developments in oral and injectable medications, improvements in drug delivery techniques, progress in oral peptide delivery, acceptance of telemedicine and digital health solutions, as well as advancements in combination therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp

What are the Key Market Players in Non-Insulin Therapies For Diabetes Market and How They’re Evolving?

Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC

What Are the Primary Growth Drivers in the Non-Insulin Therapies For Diabetes Market?

The surge in diabetes cases is projected to push the growth of non-insulin treatments in the diabetes market. Diabetes, an enduring health disorder characterised by elevated blood glucose (sugar) levels, arises when the body is unable to generate sufficient insulin or utilise the produced insulin correctly. The rising diabetes cases can be attributed to inactive lifestyles, improper diets, genetic tendencies, expanding elderly populations, obesity, ethnicity, unawareness, restricted healthcare access, and environmental elements. Non-insulin diabetes treatments serve to manage the ailment by enhancing insulin responsiveness, decreasing liver glucose production, boosting glucose absorption in muscle cells, and augmenting overall glycemic regulation. For example, a report in April 2023 by The British Diabetic Association, a diabetes charity based in the UK, revealed that 4.3 million individuals in the UK were diagnosed with diabetes. Data from 2021-22 show an increase of 148,951 cases compared to 2020-21. Moreover, over 2.4 million people in the UK are at a raised risk of developing type 2 diabetes. Thus, the surge in diabetes cases is fuelling the growth of non-insulin treatments in the diabetes market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=16494&type=smp

What Are the Leading Segments in the Global Non-Insulin Therapies For Diabetes Industry?

The non-insulin therapies for diabetes market covered in this report is segmented –

1) By Drug Class: Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Glucagon-like peptide-1 (GLP-1) Analogs, Sodium-glucose co-transporter-2 (SGLT2) Inhibitors

2) By Route Of Administration: Oral, Intramuscular

3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy

4) By Application: Monitoring, Diagnosis, Treatment, Other Applications

Subsegments:

1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs

2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide, Liraglutide, Dulaglutide, Semaglutide

7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

What Are the Key Market Trends in the Non-Insulin Therapies For Diabetes Industry?

Leading firms in the non-insulin treatments for diabetes sector are pioneering individualized diabetes management systems. They aim to improve patient results by facilitating instant monitoring, data analysis, and personalized treatment plans. This innovative system modifies treatment and supervision as per the unique needs of each patient, utilizing live data and analytics to boost care and outcomes. For example, Eli Lilly and Company, an American pharmaceutical enterprise, inaugurated the Tempo personalized diabetes management platform in November 2022. The Tempo platform incorporates three key parts: the Tempo Smart Button, the TempoSmart application, and the preloaded insulin pen named the Tempo Pen. Together, these pieces work to offer personalized guidance for adults suffering from diabetes. This innovation aims to support adults with either type 1 or type 2 diabetes and their medical teams to make knowledgeable, evidence-based treatment choices using Lilly insulins.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

What Is the Regional Outlook for the Non-Insulin Therapies For Diabetes Market?

North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16494

This Report Delivers Insight On:

1. How big is the non-insulin therapies for diabetes market, and how is it changing globally?

2. Who are the major companies in the non-insulin therapies for diabetes market, and how are they performing?

3. What are the key opportunities and risks in the non-insulin therapies for diabetes market right now?

4. Which products or customer segments are growing the most in the non-insulin therapies for diabetes market?

5. What factors are helping or slowing down the growth of the non-insulin therapies for diabetes market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model